Cambridge, November 14, 2017: Isomerase staff, invited guests and local dignitaries gathered at Chesterford Research Park on Monday 13th November to celebrate the organisation’s attainment of the Queen’s Award for Enterprise in International Trade.
The award, presented by the Lord-Lieutenant of Essex, Mrs Jennifer Tolhurst, followed a short address by Isomerase CTO, Dr Steven Moss.
Isomerase Therapeutics was co-founded in 2012 by Dr Matt Gregory, CEO and Dr Steven Moss. The company operates a dual business model offering fee-for-service contract research services to companies looking to accelerate their discovery and development in the health and life-sciences sectors. It then reinvests the profits from this activity into the development of a proprietary suite of novel drug discovery technologies, which have the potential to deliver a new generation of medicines for the treatment of cancer and infectious disease.
Isomerase’ overseas sales have grown by over 600% during the last three years and strong relationships have been built with companies and partners around the world. It now employs 27 highly skilled staff. The Queen’s Award for Enterprise in International Trade - the most prestigious corporate achievement any UK business can attain - is testament to the company’s outstanding performance to date.
Dr Matt Gregory, CEO commented: “We are delighted and very proud to receive the Queen’s Award and there are many people to thank, the most important of whom are our team. Everyone on the team – whether they have been with us from the beginning or are more recent arrivals – is a highly skilled, passionate innovator. They really are the life and soul of our company and this award belongs to each and every one of them.
“We first arrived at Chesterford Research Park well over a decade ago and the support we received in the early days from the Park team really made a difference – I look forward to being here for a number of years to come.”
Chesterford Research Park’s low-density development, set within 250 acres of impressive parkland, offers not only ultra modern and energy efficient laboratory and office space, but also central ‘hub’ facilities within The Nucleus building — which includes a restaurant, café bar, health and fitness centre and meeting and conferencing space. The Park provides an innovative, flexible and future proofed environment for both established and early stage biotechnology and pharmaceutical research and development companies. Isomerase shares the Park environment with major players such as AstraZeneca, Illumina Inc and Domainex, who have also chosen Chesterford as the base from which to advance their research and development.